Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective" by Marten J. Poley et al
- PMID: 41168611
- DOI: 10.1007/s40273-025-01551-7
Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective" by Marten J. Poley et al
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare no conflicts of interest in relation to this work. Author Contributions: All authors contributed to the manuscript conception and design and were involved with the work of the EAG. Data availability: Committee discussion and committee papers, including EAG reports, for published guidance are available through the NICE website.
Comment on
-
Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective.Pharmacoeconomics. 2025 Oct;43(10):1165-1169. doi: 10.1007/s40273-025-01522-y. Epub 2025 Jul 23. Pharmacoeconomics. 2025. PMID: 40699293 No abstract available.
References
-
- Poley MJ, et al. Cost comparisons in NICE technology appraisals: an external assessment group perspective. Pharmacoeconomics. 2025. https://doi.org/10.1007/s40273-025-01522-y . - DOI - PubMed
-
- National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. NICE process and methods [PMG36]. 2022 31 Oct 2023; Available from: https://www.nice.org.uk/process/pmg36 .
-
- National Institute for Health and Care Excellence (NICE). Cost comparison. Addendum to the Guide to the methods of technology appraisal. London: NICE; 2018.
-
- National Institute for Health and Care Excellence (NICE). Bimekizumab for treating axial spondyloarthritis. Technology appraisal guidance. Reference number:TA918. 2023; Available from: https://www.nice.org.uk/guidance/ta918 .
Publication types
LinkOut - more resources
Full Text Sources
